Search results
Showing 1051 to 1065 of 1422 results for social care
Evidence-based recommendations on infliximab (Remicade, Inflectra or Remsima), adalimumab (Humira) and golimumab (Simponi) for treating moderate to severe ulcerative colitis in adults, and on infliximab for treating severe active ulcerative colitis in children and young people of 6–17 years.
Evidence-based recommendations on point-of-care creatinine devices to assess kidney function before CT imaging with intravenous contrast. The tests are
Agenda and papers of the NICE public board meeting on 16 December 2022
from previous meetings. Update from the Department of Health and Social Care Presented by: DHSC To receive an oral update on any issues...
Pembrolizumab for gastric or gastroesophageal junction adenocarcinoma [ID1305]
Discontinued [GID-TA10244]
Nivolumab with ipilimumab for treating squamous cell carcinoma of the head and neck [ID1355]
Discontinued [GID-TA10321]
Guadecitabine for untreated acute myeloid leukaemia [ID1411]
Discontinued [GID-TA10325]
Nintedanib for treating interstitial lung disease caused by systemic sclerosis [ID1420]
Discontinued [GID-TA10427]
The MAGEC system for spinal lengthening in children with scoliosis (MT169)
Discontinued [GID-MT544]
Evidence-based recommendations on procalcitonin testing for diagnosing and monitoring sepsis (ADVIA Centaur BRAHMS PCT assay, BRAHMS PCT Sensitive Kryptor assay, Elecsys BRAHMS PCT assay, LIAISON BRAHMS PCT assay and VIDAS BRAHMS PCT assay)
Human growth hormone (somatropin) for the treatment of growth failure in children (TA188)
Evidence-based recommendations on human growth hormone (somatropin; Genotropin, Humatrope, Norditropin, NutropinAq, Omnitrope, Saizen, Zomacton) for treating growth failure in children.
NICE has developed a medtech innovation briefing (MIB) on FLEXISEQ for osteoarthritis